Key result
Nonwhite patients with HFpEF are linked to ~75% lower odds of wanting to stop medications.
Why the study?
Attitudes toward deprescribing among patients with heart failure with preserved ejection fraction (HFpEF) were not well understood.
Cohort (n=134)
No
Odds Ratio: 0.25 (95% CI 0.09–0.62)
p-value: p=0.005
The vast majority of older adults with HFpEF and polypharmacy are amenable to deprescribing and desire shared decision-making regarding their medications.
No takes yet. Share an insight, caveat, or question.
Racial disparities in HFpEF deprescribing preferences warrant clinician awareness during shared decision-making; hypothesis-generating for equity-focused interventions.
Navid et al. (2021) conducted a cohort in Heart failure with preserved ejection fraction (HFpEF) (n=134). Nonwhite race vs. White race was evaluated on Wanting to try stopping one of their medicines to see how they feel without it (OR 0.25, 95% CI 0.09-0.62, p=0.005). Among patients with HFpEF, nonwhite participants were significantly less likely to want to try stopping one of their medicines (OR 0.25; 95% CI 0.09-0.62; p=0.005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: